Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-4 Registration of securities (foreign)
- 3.1 EX-3.1
- 4.1 EX-4.1
- 4.2 EX-4.2
- 5.1 EX-5.1
- 8.1 EX-8.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.6.1 EX-10.6.1
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.20.1 EX-10.20.1
- 10.20.2 EX-10.20.2
- 10.20.3 EX-10.20.3
- 10.21 EX-10.21
- 10.21.1 EX-10.21.1
- 10.21.2 EX-10.21.2
- 10.22 EX-10.22
- 10.22.1 EX-10.22.1
- 10.22.2 EX-10.22.2
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 22.1 EX-22.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- 23.4 EX-23.4
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
MREO similar filings
Filing view
External links
Exhibit 23.4
CONSENT
OF
LATHAM & WATKINS LLP
We hereby consent to the reference to our firm name under the caption “Legal Matters” in the proxy statement/prospectus that forms a part of the Registration Statement on Form F-4 of Mereo BioPharma Group plc. In giving the foregoing consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations promulgated thereunder.
/s/ Latham & Watkins LLP | ||
January 24, 2019 |